Author

Kaja Kostyrko

Boehringer Ingelheim (Austria)ORCID 0000-0002-2842-4089Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1 Assay:metabolomics· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Andrea Olarte-San JuaniD· 2 shared Eugenio SantosiD· 2 shared Marco H. HofmanniD· 2 shared Nuria CalzadaiD· 2 shared Rósula García‐NavasiD· 2 shared Alba Díaz-Aguilera· 1 shared Alberto Fernández‐MedardeiD· 1 shared Anabel Clemente-Serrano· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Andrea Olarte-San JuanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell Death and DiseasePeer-reviewedAug 12, 2026

Targeting SOS1 synergistically enhances efficacy of BCR/ABL tyrosine kinase inhibitors and overcomes resistance in chronic myeloid leukemia

Rósula García‐Navas, Carmela Gómez, Anabel Clemente-Serrano…·Eugenio Santos

This study shows that combining SOS1 inhibitor BI-3406 with BCR/ABL TKIs like imatinib improves survival and overcomes resistance in CML models.

DOI 10.1038/s41419-026-09170-6

𝕏 PostBluesky

Cancer BiologyProceedings of the National Academy of SciencesPeer-reviewedMar 12, 2025

Pharmacological SOS1 inhibitor BI-3406 demonstrates in vivo anti-tumor activity comparable to SOS1 genetic ablation in KRAS mutant tumors

Fernando C. Baltanás, Maximilian Kramer‐Drauberg, Rósula García‐Navas…·Eugenio Santos

This study shows that the SOS1 inhibitor BI-3406 effectively reduces tumor growth in KRAS mutant cancers, similar to genetic SOS1 ablation, with comparable efficacy to another KRAS inhibitor.

16 citationstop 5%

mouseproteomics

𝕏 PostBluesky